1.Aquila, R, Malamud, TJ, Sweet, T, Kelleher, JD. The store front, Fountain House, and the rehabilitation alliance. MedGenMed. 2006; 8(3): 67.
2.Keefe, RS, Eesley, CE, Poe, MP. Defining a cognitive function decrement in schizophrenia. Biol Psychiatry. 2005; 57(6): 688–691.
3.Nuechterlein, KH, Green, MF, Kern, RS, et al. The MATRICS Consensus Cognitive Battery. Part 1: test selection, reliability and validity. Am J Psychiatry. 2008; 165(2): 203–213.
4.Lindenmayer, JP, McGurk, SR, Mueser, KT, et al. A randomized controlled trial of cognitive remediation among inpatients with persistent mental illness. Psychiatr Serv. 2008; 59(3): 241–247.
5.Chan, JY, Hirai, HW, Tsoi, KK. Can computer-assisted cognitive remediation improve employment and productivity outcomes of patients with severe mental illness? A meta-analysis of prospective controlled trials. J Psychiatr Res. 2015; 68: 293–300.
6.Kaneko, Y, Keshavan, M. Cognitive remediation in schizophrenia. Clin Psychopharmacol Neurosci. 2012; 10(3): 125–135.
7.McGurk, SR, Mueser, KT, Xie, H, et al. Cognitive enhancement treatment for people with mental illness who do not respond to supported employment: a randomized controlled trial. Am J Psychiatry. 2015; 172(9): 852–861.
8.Kurzban, S, Davis, L, Brekke, JS. Vocational, social, and cognitive rehabilitation for individuals diagnosed with schizophrenia: a review of recent research and trends. Curr Psychiatry Rep. 2010; 12(4): 345–355.
9.Folstein, MF, Folstein, SE, McHugh, PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3): 189–198.
10.Nasreddine, ZS, Phillips, NA, Bédirian, V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005; 53(4): 695–699.
11.Morosini, PL, Magliano, L, Brambilla, L, Ugolini, S, Pioli, R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000; 101(4): 323–329.
12.Nafees, B, van Hanswijck de Jonge, P, et al. Reliability and validity of the Personal and Social Performance scale in patients with schizophrenia. Schizophr Res. 2012; 140(1–3): 71–76.
13.Patterson, TL, Goldman, S, McKibbin, CL, Hughs, T, Jeste, DV. UCSD Performance-Based Skills Assessment: development of a new measure of everyday functioning for severely mentally ill adults. Schizophr Bull. 2001; 27(2): 235–245.
14.Keefe, RS, Haig, GM, Marder, SR, et al. Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia. Schizophr Bull. In press. DOI: 10.1093/schbul/sbv111.
15.Rosenheck, R, Leslie, D, Keefe, R, et al. Barriers to employment for people with schizophrenia. Am J Psychiatry. 2006; 163(3): 411–417.
16.Schonebaum, AD, Boyd, JK, Dudek, KJ. A comparison of competitive employment outcomes for the clubhouse and PACT models. Psychiatr Serv. 2006; 57(10): 1416–1420.
17.Norman, C. The Fountain House movement, an alternative rehabilitation model for people with mental health problems, members’ descriptions of what works. Scand J Caring Sci. 2006; 20(2): 184–192.
18.Howes, OD, Kapur, S. The dopamine hypothesis of schizophrenia: version III—the final common pathway. Schizophr Bull. 2009; 35(3): 549–562.
19.Howes, O, McCutcheon, R, Stone, J. Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol. 2015; 29(2): 97–115.
20.Jones, CK, Byun, N, Bubser, M. Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology. 2012; 37(1): 16–42.
21.Barch, DM, Ceaser, A. Cognition in schizophrenia: core psychological and neural mechanisms. Trends Cogn Sci. 2012; 16(1): 27–34.
22.Nielsen, RE, Levander, S, Kjaersdam Telléus, G, Jensen, SO, Østergaard Christensen, T, Leucht, S. Second-generation antipsychotic effect on cognition in patients with schizophrenia—a meta-analysis of randomized clinical trials. Acta Psychiatr Scand. 2015; 131(3): 185–196.
23.Kantrowitz, JT, Javitt, DC. Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models. Clin Schizophr Relat Psychoses. 2010; 4(3): 189–200.
24.Tsapakis, EM, Travis, MJ. Glutamate and psychiatric disorders. Adv Psychiatr Treat. 2002; 8(3): 189–197.
25.Moghaddam, B. Bringing order to the glutamate chaos in schizophrenia. Neuron. 2003; 40(5): 881–884.
26.Kantrowitz, JT, Javitt, DC. Glutamate: new hope for schizophrenia treatment. Curr Psychiatry. 2011; 10(4): 69–74.
27.Citrome, L. Neurochemical models of schizophrenia: transcending dopamine. Curr Psychiatry. 2011; 10(9): S10–S14.
28.Stahl, MS. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 3rd ed. New York: Cambridge University Press; 2008.
29.Kantrowitz, JT, Javitt, DC. N-Methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res Bull. 2010; 83(3–4): 108–121.
30.Citrome, L. Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains. J Clin Psychiatry. 2014; 75(Suppl 1): 21–26.
31.Iwata, Y, Nakajima, S, Suzuki, T, et al. Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials. Mol Psychiatry. In press. DOI: 10.1038/mp.2015.68.
32.Birks, J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;(1): CD005593.
33.Singh, J, Kour, K, Jayaram, MB. Acetylcholinesterase inhibitors for schizophrenia. Cochrane Database Syst Rev. 2012; 1: CD007967.
34.Young, JW, Geyer, MA. Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia. Biochem Pharmacol. 2013; 86(8): 1122–1132.
35.Levin, ED, McClernon, FJ, Rezvani, AH. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl). 2006; 184(3–4): 523–539.
36.Huang, M, Felix, AR, Flood, DG, et al. The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens. Psychopharmacology (Berl). 2014; 231(23): 4541–4551.
37.Prickaerts, J, van Goethem, NP, Chesworth, R, et al. EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors. Neuropharmacology. 2012; 62(2): 1099–1110.
38.Keefe, RS, Meltzer, HA, Dgetluck, N, et al. Randomized, double-blind, placebo-controlled study of encenicline, an α7 nicotinic acetylcholine receptor agonist, as a treatment for cognitive impairment in schizophrenia. Neuropsychopharmacology. In press. DOI: 10.1038/npp.2015.176.
39.Deardorff, WJ, Shobassy, A, Grossberg, GT. Safety and clinical effects of EVP-6124 in subjects with Alzheimer’s disease currently or previously receiving an acetylcholinesterase inhibitor medication. Expert Rev Neurother. 2015; 15(1): 7–17.
41.Carruthers, SP, Gurvich, CT, Rossell, SL. The muscarinic system, cognition and schizophrenia. Neurosci Biobehav Rev. 2015; 55: 393–402.
42.Köster, LS, Carbon, M, Correll, CU. Emerging drugs for schizophrenia: an update. Expert Opin Emerg Drugs. 2014; 19(4): 511–531.
43.Green, MF, Nuechterlein, KH, Gold, JM, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry. 2004; 56(5): 301–307.
44.Buchanan, RW, Freedman, R, Javitt, DC, Abi-Dargham, A, Lieberman, JA. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull. 2007; 33(5): 1120–1130.
45.Goff, DC, Hill, M, Barch, D. The treatment of cognitive impairment in schizophrenia. Pharmacol Biochem Behav. 2011; 99(2): 245–253.